Veracyte is a global leader in diagnostic solutions that empower clinicians to make informed decisions in cancer care. Committed to transforming cancer diagnosis and treatment, Veracyte offers a comprehensive portfolio of molecular tests targeting various cancer types including thyroid, prostate, breast, bladder, and interstitial lung disease. Their signature products, such as the Afirma® Genomic Sequencing Classifier for thyroid cancer and the Decipher® Prostate Genomic Classifier, provide high-value insights, enabling clinicians to navigate complex decision-making processes with confidence.

Veracyte's innovative approach is rooted in collaboration with healthcare professionals and rigorous scientific research, ensuring reliable and actionable outcomes. With a mission to elevate standards of care globally, Veracyte aims to make their advanced diagnostics accessible through a centralized laboratory model and in vitro diagnostics (IVD). Additionally, their engagement in biopharma services and commitment to environmental, social, and governance (ESG) initiatives reflects their dedication to a sustainable and equitable future in healthcare